1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug Discovery Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug Discovery Market, by End User Type
8.1.1. Pharmaceutical Companies
8.1.1.1. Market Revenue and Forecast
8.1.2. CROs
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Drug Discovery Market, by Drug Type
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast
10.1. Drug Discovery Market, by Technology
10.1.1. High Throughput Screening
10.1.1.1. Market Revenue and Forecast
10.1.2. Pharmacogenomics
10.1.2.1. Market Revenue and Forecast
10.1.3. Combinatorial Chemistry
10.1.3.1. Market Revenue and Forecast
10.1.4. Nanotechnology
10.1.4.1. Market Revenue and Forecast
10.1.5. Other Technologies
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by End User
11.1.2. Market Revenue and Forecast, by Drug Type
11.1.3. Market Revenue and Forecast, by Technology
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by End User
11.1.4.2. Market Revenue and Forecast, by Drug Type
11.1.4.3. Market Revenue and Forecast, by Technology
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by End User
11.1.5.2. Market Revenue and Forecast, by Drug Type
11.1.5.3. Market Revenue and Forecast, by Technology
11.2. Europe
11.2.1. Market Revenue and Forecast, by End User
11.2.2. Market Revenue and Forecast, by Drug Type
11.2.3. Market Revenue and Forecast, by Technology
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by End User
11.2.4.2. Market Revenue and Forecast, by Drug Type
11.2.4.3. Market Revenue and Forecast, by Technology
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by End User
11.2.5.2. Market Revenue and Forecast, by Drug Type
11.2.5.3. Market Revenue and Forecast, by Technology
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by End User
11.2.6.2. Market Revenue and Forecast, by Drug Type
11.2.6.3. Market Revenue and Forecast, by Technology
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by End User
11.2.7.2. Market Revenue and Forecast, by Drug Type
11.2.7.3. Market Revenue and Forecast, by Technology
11.3. APAC
11.3.1. Market Revenue and Forecast, by End User
11.3.2. Market Revenue and Forecast, by Drug Type
11.3.3. Market Revenue and Forecast, by Technology
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by End User
11.3.4.2. Market Revenue and Forecast, by Drug Type
11.3.4.3. Market Revenue and Forecast, by Technology
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by End User
11.3.5.2. Market Revenue and Forecast, by Drug Type
11.3.5.3. Market Revenue and Forecast, by Technology
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by End User
11.3.6.2. Market Revenue and Forecast, by Drug Type
11.3.6.3. Market Revenue and Forecast, by Technology
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by End User
11.3.7.2. Market Revenue and Forecast, by Drug Type
11.3.7.3. Market Revenue and Forecast, by Technology
11.4. MEA
11.4.1. Market Revenue and Forecast, by End User
11.4.2. Market Revenue and Forecast, by Drug Type
11.4.3. Market Revenue and Forecast, by Technology
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by End User
11.4.4.2. Market Revenue and Forecast, by Drug Type
11.4.4.3. Market Revenue and Forecast, by Technology
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by End User
11.4.5.2. Market Revenue and Forecast, by Drug Type
11.4.5.3. Market Revenue and Forecast, by Technology
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by End User
11.4.6.2. Market Revenue and Forecast, by Drug Type
11.4.6.3. Market Revenue and Forecast, by Technology
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by End User
11.4.7.2. Market Revenue and Forecast, by Drug Type
11.4.7.3. Market Revenue and Forecast, by Technology
11.5. Latin America
11.5.1. Market Revenue and Forecast, by End User
11.5.2. Market Revenue and Forecast, by Drug Type
11.5.3. Market Revenue and Forecast, by Technology
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by End User
11.5.4.2. Market Revenue and Forecast, by Drug Type
11.5.4.3. Market Revenue and Forecast, by Technology
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by End User
11.5.5.2. Market Revenue and Forecast, by Drug Type
11.5.5.3. Market Revenue and Forecast, by Technology
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GlaxoSmithKline PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Agilent Technologies Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Eli Lilly and Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F. Hoffmann-La Roche Ltd
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bayer AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Abbott Laboratories Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Shimadzu Corp
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
